1,3-Benzenedicarboxamide, N1-(1-propyl-1H-benzimidazol-2-yl)-
Takinib
CAS: 1111556-37-6
Molecular Formula: C18H18N4O2
1,3-Benzenedicarboxamide, N1-(1-propyl-1H-benzimidazol-2-yl)- - Names and Identifiers
1,3-Benzenedicarboxamide, N1-(1-propyl-1H-benzimidazol-2-yl)- - Physico-chemical Properties
| Molecular Formula | C18H18N4O2 |
| Molar Mass | 322.36 |
| Density | 1.30±0.1 g/cm3(Predicted) |
| Solubility | DMSO : 6.8 mg/mL (21.09 mM; Need ultrasonic and warming) |
| pKa | 12.13±0.43(Predicted) |
| Storage Condition | -20°C |
| In vitro study | Takinib is an inhibitor of both auto-phosphorylated and non-phosphorylated TAK1 and binds to the ATP binding pocket of TAK1 to slow down the rate-limiting step in the activation of tak1. Takinib has significant inhibitory activity against six threonine/serine kinases, including TAK1, IRAK4, IRAK1, GCK, CLK2 and MINK1 at a concentration of 10 μm, TAK1/MAP3K7 was the most efficiently inhibited kinase with an IC50 of 9.5 nM. Treatment with Takinib induces TNF-α dependent apoptosis in RA cell models and metastatic breast cancer. Takinib does not inhibit MAP2Ks or MAP3Ks family members such as MKK6/MAP2K6, MEKK1/ MAP3K1, MKK1/MAP2K1. Takinib also had no inhibitory effect on MAP3K5/ASK1. |
1,3-Benzenedicarboxamide, N1-(1-propyl-1H-benzimidazol-2-yl)- - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.102 ml | 15.511 ml | 31.021 ml |
| 5 mM | 0.62 ml | 3.102 ml | 6.204 ml |
| 10 mM | 0.31 ml | 1.551 ml | 3.102 ml |
| 5 mM | 0.062 ml | 0.31 ml | 0.62 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: Takinib Visit Supplier Webpage Request for quotationCAS: 1111556-37-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Takinib Visit Supplier Webpage Request for quotationCAS: 1111556-37-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History